Source: Dana-Farber Cancer Institute
Date: December 6, 2009
Summary:
A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results from Dana-Farber Cancer Institute investigators. The trial was designed to determine whether the drug bortezomib (trade name Velcade®), when added to routine agents (tacrolimus, methotrexate), can improve control of graft-versus-host disease (GVHD) and improve immune system recovery following a transplant from a mismatched-unrelated dono
